Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs operate by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances enhance insulin production and suppress gl

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts i